Triangle Business Journal Selects Meade for Guest Column

November 10, 2014 · Leave a comment

In the wake of the Sunshine Act’s Open Payments database launch, press detailing payments made to doctors by the pharma and medical device industries is fueling speculation about the negative impact this development could have on industry.

Given the Raleigh-Durham area’s top medical centers and concentration of pharmaceutical/device manufacturers, the release of this information could have a lot of implications on the Triangle’s economy, in particular. As the region’s leading source of business news, the Triangle Business Journal turned to Thought Leader Select’s Paul Meade for his expert insight into these concerns:

TAGS:                                                   

Meade Featured as Sunshine Disclosure Expert

October 16, 2014 · Leave a comment

As disclosures of life science industry payments to healthcare professionals continue with rollouts such as the Centers for Medicare and Medicaid Services’ Open Payments Database in late September, Thought Leader Select’s Paul Meade has been a sought-after expert on the impact of these disclosures on industry collaborations with key opinion leaders in medicine.

Meade, the company’s founder and president, spent 25 years leading brand and strategy teams at global drug manufacturers Merck and GlaxoSmithKline and understands the critical importance that key opinion leader interactions bring to the table in both medical affairs and commercialization efforts for pharmaceutical, biotechnology, and medical device companies.

In the attached FDA News story (subscription required), Meade provided context for greater understanding on the recently-released CMS database numbers totaling some $3.5 billion in payments to physicians.  He encouraged the media and public to dig deeper in order see how honoraria and especially travel and meal costs can quickly add up as companies engage leading physicians on a broad range of scientific activities that drive product development and peer awareness that ultimately improve patient outcomes and quality of life measures over time.

For more information or media inquiries, please contact Brian Castle, Director of ... read more »

TAGS:                                                     

Thought Leader Select Customizes KOL Identification Methodologies in Support of Global Diabetes Initiatives

August 18, 2014 · Leave a comment

By Brian Castle

Throughout most of 2014, Thought Leader Select has been privileged to work with a top-five global biopharmaceutical giant in support of its diabetes portfolio in across the globe. 

For this particular engagement, across several countries with cultural and language differences, stakeholders within the client company needed a customized approach.  The chosen approach must leave no doubt within the organization—nor among the external group of key opinion leaders (KOLs) chosen for engagement—that the company had taken a measured path to selecting the right members of the medical community for outreach and support in diabetes.

From our work with more than 50 leading biotechnology, pharmaceutical, and medical device companies over the last decade, we know the importance of satisfying competing visions for KOL selection.  Some prefer an objective methodology based on research by subject matter experts, while others prefer a guided process of nominations by trained professionals, often former practitioners themselves, tasked with outreach to leaders in the medical community.

We also know the importance of the respect that the KOLs themselves have for the company and its selection process.  KOLs most obviously and critically form their judgments about companies through their personal interactions with industry representatives at every level, from commercial executives at regional and global headquarters to more locally-based ... read more »

TAGS:                                       

Biopharma Re-engages Thought Leader Select for KOL Work in Bacterial Infections

December 10, 2013 · Leave a comment

December 10, 2013 (CHAPEL HILL, NC) Thought Leader Select, a consulting firm to the life sciences industries, recently earned a new client engagement to support key opinion leader (KOL) strategies for new treatments in the area of bacterial infections.

The client company, an industry leader in the development of medications to treat various bacterial infections, tabbed North Carolina’s Thought Leader Select to help optimize KOL collaborations in support of its portfolio of medicines for treating anti-biotic-associated infections, including the gram positive bacterial infection, C. difficile.

According to the Centers for Disease Control, C. Difficile is related to the deaths of more than 14,000 Americans each year. Those most at risk are older adults who take antibiotics and receive care at healthcare institutions such as hospitals and clinics.

Thought Leader Select, headquartered in the Research Triangle region of North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading medical experts, the health care professionals that advance treatment options and promote better public health at regional, national, and global levels.

Earlier this year, Thought Leader Select provided in-house research resulting in foundational data and analytics to facilitate new KOL relationships for the client company in the area of gram ... read more »

TAGS:                                             

US Biopharma Chooses Thought Leader Select for KOL Initiatives in Lupus

December 4, 2013 · Leave a comment

December 4, 2013 (CHAPEL HILL, NC) Thought Leader Select, a consulting firm to the life sciences industries, is working with a U.S. biopharmaceutical company on key opinion leader (KOL) initiatives in systemic lupus.

The client company, a leader in developing new medicines for difficult-to-treat auto-immune and inflammatory disorders, chose North Carolina’s Thought Leader Select to assist them with upcoming and ongoing initiatives with national and regional KOLs in the rheumatology community.

The Lupus Foundation of America estimates that there are approximately 1.5 million Americans living with lupus.  About 70 percent of these cases are estimated to be systemic in nature and can affect almost any organ or system in the body, including the skin, joints, lungs, kidneys, heart, nervous system, and brain.   Lupus is a major women’s health issue, with 90 percent of lupus cases affecting women. The Foundation also reports that lupus adversely affects minority women in groups such as African and Native Americans and Latin Americans in rates that are two to three times greater than the rate of incidence among U.S. Caucasian women.

Thought Leader Select, headquartered in the Research Triangle region of North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading ... read more »

TAGS:                                                         

Global Pharma Giant Tabs Thought Leader Select to Optimize KOL Engagements in Diabetes

November 26, 2013 · Leave a comment

November 26, 2013 (CHAPEL HILL, NC) Thought Leader Select, a consulting firm to the life sciences industries, recently earned new work in support of global key opinion leader (KOL) initiatives in diabetes for a top five global biopharmaceutical company.

The client company, one of the world’s top ten industry leaders in the development of medications across multiple therapeutic areas, tabbed North Carolina’s Thought Leader Select to assist them with upcoming and ongoing initiatives with global KOLs in diabetes, in support of its portfolio of insulin and other medications.

According to International Diabetes Federation estimates, nearly 400 million people worldwide suffer from some form of diabetes.  That number is expected to escalate to nearly 600 million by 2035.

Thought Leader Select, headquartered in the Research Triangle region of North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading medical experts, the health care professionals that advance treatment options and promote better public health at regional, national, and global levels.

For this global diabetes initiative, Thought Leader Select’s in-house research team will identify nearly 200 global KOLs in diabetes from a range of countries and regions, including the United States and Canada, western Europe, China, Latin America, Asia, and ... read more »

TAGS:                                                           

Biopharma Giant Tabs Thought Leader Select for Initiatives in Companion Diagnostics for Oncology Products

July 9, 2013 · Leave a comment

July 9, 2013 (CHAPEL HILL, NC) A global biopharmaceutical leader has chosen Thought Leader Select to perform critical research and advisory work in support of key opinion leader initiatives advancing companion diagnostics for oncology medications.

Thought Leader Select, headquartered in Chapel Hill, North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies, as they reach out to and collaborate with leading medical experts to advance treatment options and promote better health worldwide.

For the engagement, Thought Leader Select’s in-house research team will identify and profile dozens of leading Canadian medical experts in pathology, with a focus on KOLs who have experience in developing companion diagnostics for cancer treatments. The company will also assess the top Canadian medical centers of excellence in pathology, delivering engagement plans that will drive interactions among the biopharma client company and its partners in medicine.

The client company, as it develops companion diagnostics for cancer medications, seeks understanding of the provincial reimbursement process and market access climate for such products, as well as learning the degrees to which medical centers of excellence optimize cancer treatment through the use of companion diagnostics.

Thought Leader Select’s work will combine the company’s objective, validated assessment methodology applied to the skills and experience of key opinion leaders in medicine with a series ... read more »

TAGS:                                                                           

Global Pharmas Choose Thought Leader Select as Vendor of Choice for KOL Initiatives

June 25, 2013 · Leave a comment

(CHAPEL HILL, NC) Canadian subsidiaries of a pair of top-15 global biopharmaceutical companies have appointed Thought Leader Select as their preferred research and engagement advisor for key opinion leader initiatives in multiple therapeutic areas.

Thought Leader Select, headquartered in Chapel Hill, North Carolina, provides research and advisory services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies, as they reach out to and collaborate with leading medical experts to advance treatment options and promote better health worldwide.

Each company has approved Thought Leader Select as its preferred vendor for a variety of projects and retained advisory services centering on the work of key opinion leaders and centers of excellence in medicine.  Key opinion leaders, also known as thought leaders and key external experts, lead the medical field with their research, clinical practice, publishing in scientific journals, patient advocacy, treatment guidelines, and more. Centers of excellence include the high-impact teaching hospitals, medical schools, specialty clinics, and research foundations known for breakthrough research and cutting-edge clinical practice.

For the coming set of engagements, Thought Leader Select will profile the skills and experience of key opinion leaders in cardiology, gastroenterology, and genetics, as the projects center around treatments for heart failure, opioid-induced constipation, and a collection of rare and orphan diseases.   Known for the versatility of applications for its ... read more »

TAGS:                                                         

US Biopharma Retains Thought Leader Select for GI Initiatives with KOLs, Centers of Excellence

June 13, 2013 · Leave a comment

June 13, 2013 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in gastroenterology with a leading U.S. biopharmaceutical company.

The company, a global leader in drug development for products aiding patients in recovery from a variety of gastrointestinal surgeries, approached Thought Leader Select for support with planned initiatives with key opinion leaders and centers of excellence in the field.

Thought Leader Select is identifying and profiling thought leaders in colorectal and general surgery across the United States.  The in-house research group at Thought Leader Select is applying its objective, validated methodology to assess the skills and experiences, as well as the clinical and research interests, of KOLs specializing in surgery of the colon, rectum, and bowels.

Known for the versatility of applications for its in-house research, Thought Leader Select’s advisory team will also plan engagement strategies to optimize the talents and contributions that the key opinion leaders will bring to several initiatives for the client company, including late-stage clinical trial work, as well as publication and speaking opportunities. The KOLs will also work on issues within appropriate regulatory bodies, as well as patient advocacy and awareness, and treatment guidelines involvement.

In addition to its work with key opinion leaders, Thought Leader Select’s research group ... read more »

TAGS:                                                     

Canadian Pharma Chooses Thought Leader Select for COPD Key Opinion Leader Engagement Strategy

December 20, 2012 · Leave a comment

December 20, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in pulmonology with a top Canadian biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating chronic obstructive pulmonary disorder (COPD), approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces.  Having already worked with Thought Leader Select to form rosters of key opinion leaders in Canadian rheumatology and oncology circles, the company will formulate its panel of key experts in pulmonology by deploying Thought Leader Select’s team to assess the skills and experiences of physician specialists across the country.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of these leading experts in multiple areas where they collaborate to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.  Among these ... read more »

TAGS:                                                           

Older posts »